Dynavax Technologies Corporation

NasdaqGS DVAX

Dynavax Technologies Corporation Price to Sales Ratio (P/S) on January 14, 2025: 6.29

Dynavax Technologies Corporation Price to Sales Ratio (P/S) is 6.29 on January 14, 2025, a -20.55% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Dynavax Technologies Corporation 52-week high Price to Sales Ratio (P/S) is 7.96 on January 23, 2024, which is 26.58% above the current Price to Sales Ratio (P/S).
Dynavax Technologies Corporation 52-week low Price to Sales Ratio (P/S) is 5.17 on October 10, 2024, which is -17.76% below the current Price to Sales Ratio (P/S).
Dynavax Technologies Corporation average Price to Sales Ratio (P/S) for the last 52 weeks is 6.33.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGS: DVAX

Dynavax Technologies Corporation

CEO	Mr. Ryan Spencer
IPO Date	Feb. 19, 2004
Location	United States
Headquarters	2100 Powell Street
Employees	408
Sector	Health Care
Industries Vaccines Biotechnology Pharmaceuticals

Description

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Key trends

Past 5 years